An intriguing feature of T-DXd has been its efficacy not only in patients with HER2-positive disease but also in HER2 low breast cancer, which is defined as 1+ by immunohistochemistry (IHC) or 2+ by IHC and negative by Fluorescence in situ hybridization (FISH). This evidence concerns the gene ERBB2 and breast carcinoma.